Home » Stocks » OptiNose

OptiNose, Inc. (OPTN)

Stock Price: $3.78 USD 0.15 (4.13%)
Updated Oct 22, 2020 4:00 PM EDT - Market closed
After-hours: $3.65 -0.13 (-3.44%) Oct 22, 7:52 PM

Stock Price Chart

Key Info

Market Cap 196.53M
Revenue (ttm) 40.81M
Net Income (ttm) -108.51M
Shares Out 51.99M
EPS (ttm) -2.46
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 22, 2020
Last Price $3.78
Previous Close $3.63
Change ($) 0.15
Change (%) 4.13%
Day's Open 3.81
Day's Range 3.75 - 4.25
Day's Volume 666,715
52-Week Range 3.28 - 11.66

More Stats

Market Cap 196.53M
Enterprise Value 176.21M
Earnings Date (est) Nov 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 51.99M
Float 30.38M
EPS (basic) -2.45
EPS (diluted) -2.46
FCF / Share -1.86
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 6.93M
Short Ratio 18.50
Short % of Float 22.82%
Beta 0.78
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 4.82
PB Ratio 16.00
Revenue 40.81M
Operating Income -91.62M
Net Income -108.51M
Free Cash Flow -85.19M
Net Cash 20.32M
Net Cash / Share 0.39
Gross Margin 71.88%
Operating Margin -224.48%
Profit Margin -265.90%
FCF Margin -208.75%
ROA -35.83%
ROE -267.66%
ROIC -119.60%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$17.50*
(362.96% upside)
Low
13.0
Current: $3.78
High
20.0
Target: 17.50
*Average 12-month price target from 6 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018201720162015
Revenue34.637.07-47.500.09
Revenue Growth390.18%--55782.35%-
Gross Profit29.345.48-47.500.09
Operating Income-95.60-100-48.5325.32-28.08
Net Income-110-107-48.9022.61-28.31
Shares Outstanding41.8839.7711.004.054.05
Earnings Per Share-2.63-2.68-5.630.32-9.97
Operating Cash Flow-90.82-91.82-35.6821.72-28.71
Capital Expenditures-0.56-1.69-2.41-0.22-0.08
Free Cash Flow-91.37-93.51-38.0921.51-28.79
Cash & Equivalents14720123536.8015.20
Total Debt74.5372.5071.8615.2614.48
Net Cash / Debt72.6112816321.540.72
Assets17321724141.5516.01
Liabilities11198.3886.6424.5822.34
Book Value61.58119154-151-161
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name OptiNose, Inc.
Country United States
Employees 221
CEO Peter Kaighn Miller

Stock Information

Ticker Symbol OPTN
Stock Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Unique Identifier NASDAQ: OPTN
IPO Date October 13, 2017

Description

OptiNose, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps. It is also developing XHANCE, which is in Phase IIIb clinical trial for the treatment of chronic sinusitis; and OPN-300 for the treatment of Prader-Willi syndrome, a rare genetic obesity disorder, as well as autism spectrum disorder. The company has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail (sumatriptan nasal powder) to treat migraine in adults; and Inexia Limited to develop, manufacture, import, and sale products containing orexin receptor agonist and/or orexin receptor positive modulator molecules for the treatment, diagnosis, or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation. OptiNose, Inc. was founded in 2010 and is headquartered in Yardley, Pennsylvania.